BOSTON--(BUSINESS WIRE)--Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced its participation in the BTIG Biotech Conference and the Stifel Healthcare Conference. Details include:
- Christopher D.T. Guiffre, J.D., M.B.A., Chief Financial Officer and Chief Operating Officer, will speak at the BTIG Biotech Conference on October 25 at 9:30 a.m. at the Langham Hotel in New York.
- Corey McCann, M.D., Ph.D., President and CEO, will present at the Stifel Healthcare Conference on November 13, at 11:45 a.m. at the Lotte New York Palace Hotel.
Pear Therapeutics is a privately held, prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious disease.
About Pear Therapeutics
Pear Therapeutics is the
leader in prescription digital therapeutics. We aim to redefine medicine
by discovering, developing, and delivering clinically validated
software-based therapeutics to provide better outcomes for patients,
smarter engagement and tracking tools for clinicians, and cost-effective
solutions for payers. Pear has a pipeline of
products and product candidates across therapeutic areas,
including mental health disorders, severe insomnia, and
multiple sclerosis. Our lead product, reSET®, treats Substance
Use Disorder (SUD) and was the first prescription digital therapeutic to
receive marketing authorization from the FDA to treat disease. Pear’s
second product, reSET-O™, for the treatment of Opioid Use Disorder
(OUD), is currently under FDA review with Breakthrough Designation. For
more information, visit us at www.peartherapeutics.com.
